{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T17:10:03Z","timestamp":1768410603839,"version":"3.49.0"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This double\u2010blind study evaluated the cardiac safety of amiselimod. Healthy adults (n = 190) were randomized (2:1:1) to receive (1) oral placebo (day \u22121), followed by oral amiselimod (days 1\u201326), which was upwardly titrated from 0.4 to 1.6 mg once daily to achieve steady\u2010state concentrations comparable with 0.4 (therapeutic) and 0.8 mg (supratherapeutic) once daily, and placebo (day 27); (2) placebo (day \u22121), oral moxifloxacin 400 mg (day 1; positive control), followed by placebo (days 1\u201327); or (3) placebo (days \u22121 to 26), followed by moxifloxacin 400 mg (day 27). No participant had a corrected QT interval by Fredericia (QTcF) &gt;500 milliseconds or a change from baseline (dQTcF) &gt;60 milliseconds. The upper limits of the 90%CIs for the differences in least\u2010squares mean difference in dQTcF between amiselimod and placebo on days 13 and 26 were &lt;10 milliseconds. Area under the concentration\u2010time curve from 0 to 23.5 hours after dosing and maximum plasma concentration of amiselimod and amiselimod\u2010P (active metabolite) at steady\u2010state concentrations for the 0.8\u2010mg dose on day 26 were approximately double that observed with the 0.4\u2010mg dose on day 13. All adverse events were mild to moderate in severity, and no deaths occurred. Amiselimod did not have any clinically relevant effect on the QTcF interval.<\/jats:p>","DOI":"10.1002\/cpdd.1210","type":"journal-article","created":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T08:19:44Z","timestamp":1674893984000},"page":"236-248","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Randomized, Double\u2010Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy Volunteers"],"prefix":"10.1002","volume":"12","author":[{"given":"Jimin","family":"Lee","sequence":"first","affiliation":[{"name":"Bausch Health US, LLC  Bridgewater New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Lester","sequence":"additional","affiliation":[{"name":"Celerion  Tempe Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"O'Reilly","sequence":"additional","affiliation":[{"name":"Celerion  Tempe Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezra R.","family":"Lowe","sequence":"additional","affiliation":[{"name":"Bausch Health US, LLC  Bridgewater New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal E.","family":"Slatkin","sequence":"additional","affiliation":[{"name":"Salix Pharmaceuticals  Bridgewater New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Franklin","sequence":"additional","affiliation":[{"name":"Salix Pharmaceuticals  Bridgewater New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Israel","sequence":"additional","affiliation":[{"name":"Bausch Health US, LLC  Bridgewater New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,1,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226154"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13641"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2010.10.005"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13203"},{"issue":"1","key":"e_1_2_8_6_1","first-page":"11","article-title":"Role of sphingosine 1\u2010phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus","volume":"3","author":"Chiba K","year":"2006","journal-title":"Cell Mol Immunol"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab201"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30192-2"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320966385"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-062411-130916"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15744"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44845-5"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.02.011"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2014.09.006"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052643"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.06.028"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511410344"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512438456"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2018.1525508"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517728343"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1003"},{"issue":"11","key":"e_1_2_8_23_1","first-page":"21","article-title":"Evolution of the thorough QT\/QTc study","volume":"7","author":"Wheeler W","year":"2010","journal-title":"Regulatory Rapporteur"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061324"},{"issue":"1","key":"e_1_2_8_25_1","first-page":"66","article-title":"Application of population pharmacokinetics\/pharmaco\u2010dynamics (PopPK\u2010PD) for selection of optimal dose of amiselimod [abstract","volume":"43","author":"Inoue S","year":"2016","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4109"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1210","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.1210","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T16:22:08Z","timestamp":1692375728000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,28]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1002\/cpdd.1210"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1210","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,28]]},"assertion":[{"value":"2022-03-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}